Debio 4326-301: An open-label, single-arm, multi-center, Phase 3 study on the efficacy, safety, and pharmacokinetics of Debio 4326, a triptorelin 12-month formulation, in pediatric participants who are receiving gonadotropin-releasing hormone agonist therapy for central precocious puberty
study on the efficacy, safety and pharmacokinetics of Debio 4326 in pediatric participants who are receiving gonadotropin-releasing hormone agonist therapy for central precocious puberty
Why this Research Matters
Interventional
Who can Participate
Child and Teen
Central precocious puberty
Study ID
Protocol Number: 23-2241
Meet the Team
Principal Investigator